S1RP34 Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Sarepta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.59 |
| 52 Week High | US$45.78 |
| 52 Week Low | US$28.77 |
| Beta | 0.75 |
| 1 Month Change | -13.02% |
| 3 Month Change | -1.53% |
| 1 Year Change | -5.76% |
| 3 Year Change | 63.42% |
| 5 Year Change | n/a |
| Change since IPO | -22.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| S1RP34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -1.0% | 0.4% | 2.6% |
| 1Y | -5.8% | 0.3% | -6.1% |
Return vs Industry: S1RP34 underperformed the BR Biotechs industry which returned 0.3% over the past year.
Return vs Market: S1RP34 matched the BR Market which returned -6.1% over the past year.
Price Volatility
| S1RP34 volatility | |
|---|---|
| S1RP34 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in BR Market | 9.8% |
| 10% least volatile stocks in BR Market | 3.2% |
Stable Share Price: S1RP34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: S1RP34's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,314 | Doug Ingram | www.sarepta.com |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Sarepta Therapeutics, Inc. Fundamentals Summary
| S1RP34 fundamental statistics | |
|---|---|
| Market cap | R$58.77b |
| Earnings (TTM) | R$694.50m |
| Revenue (TTM) | R$9.35b |
84.6x
P/E Ratio6.3x
P/S RatioIs S1RP34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S1RP34 income statement (TTM) | |
|---|---|
| Revenue | US$1.64b |
| Cost of Revenue | US$1.03b |
| Gross Profit | US$609.29m |
| Other Expenses | US$487.45m |
| Earnings | US$121.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 1.28 |
| Gross Margin | 37.14% |
| Net Profit Margin | 7.43% |
| Debt/Equity Ratio | 100.5% |
How did S1RP34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 02:10 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sarepta Therapeutics, Inc. is covered by 54 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Zhiqiang Shu | Berenberg |